Viridian Therapeutics, Inc. VRDN Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s accrued expenses?
- Viridian Therapeutics, Inc. (VRDN) reported accrued expenses of $8.36M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Viridian Therapeutics, Inc.'s accrued expenses increased by 64.1% year-over-year, from $5.1M to $8.36M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s accrued expenses has grown at a 15.2% compound annual growth rate (CAGR), from $9.7M to $19.66M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.